Steven D. Green

Family Medicine

217 S 3rd St
Danville, KY 40422

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 09, 2026

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.

Journal: Blood advances

Published: November 06, 2025

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

Journal: Blood advances

Published: November 06, 2025

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.

Journal: Leukemia & lymphoma

Published: December 27, 2024

Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab - case report and review of the literature.

Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab - case report and review of the literature.

Journal: Annals of hematology

Published: November 26, 2024

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 11, 2024

Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.

Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.

Journal: Leukemia research

Published: June 05, 2024

How I treat secondary acute myeloid leukemia.

How I treat secondary acute myeloid leukemia.

Journal: Blood

Published: May 14, 2024

Acute leukemia with KMT2A rearrangement: A master of disguise.

Acute leukemia with KMT2A rearrangement: A master of disguise.

Journal: Leukemia research reports

Published: March 18, 2024

Association of platelet satellitism with immune thrombocytopenia: A case report and review of literature.

Association of platelet satellitism with immune thrombocytopenia: A case report and review of literature.

Journal: EJHaem

Published: March 01, 2024

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

Journal: Blood cancer journal

Published: July 08, 2023

TP53 or Not TP53: That Is the Question.

TP53 or Not TP53: That Is the Question.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 12, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026